PURPOSE: To determine whether down-regulation of transcription factor signaling during pregnancy disrupts the induction of efflux transporters in type I diabetic mice. METHODS: Type I diabetes was induced in female C57BL/6 mice with multiple low dose intraperitoneal injections of streptozotocin (STZ) at least 2 weeks prior to mating with normoglycemic male mice. On gestation day 14, livers were collected from vehicle- and STZ-treated non-pregnant and pregnant mice for quantification of efflux transporter and transcription factor signaling. RESULTS: STZ treatment up-regulated expression of Mrp1-5, Mdr1, Abcg5, Abcg8, Bcrp, and Bsep mRNA and/or protein in the livers of non-pregnant mice. Interestingly, little to no change in transporter expression was observed in STZ-treated pregnant mice compared to vehicle- and STZ-treated non-pregnant mice. CONCLUSIONS: This study demonstrates the opposing regulation of hepatobiliary efflux transporters in response to diabetes and pregnancy and points to PPARγ, Nrf2, and FXR as candidate pathways underlying the differential expression of transporters.
PURPOSE: To determine whether down-regulation of transcription factor signaling during pregnancy disrupts the induction of efflux transporters in type I diabeticmice. METHODS:Type I diabetes was induced in female C57BL/6 mice with multiple low dose intraperitoneal injections of streptozotocin (STZ) at least 2 weeks prior to mating with normoglycemic male mice. On gestation day 14, livers were collected from vehicle- and STZ-treated non-pregnant and pregnant mice for quantification of efflux transporter and transcription factor signaling. RESULTS:STZ treatment up-regulated expression of Mrp1-5, Mdr1, Abcg5, Abcg8, Bcrp, and Bsep mRNA and/or protein in the livers of non-pregnant mice. Interestingly, little to no change in transporter expression was observed in STZ-treated pregnant mice compared to vehicle- and STZ-treated non-pregnant mice. CONCLUSIONS: This study demonstrates the opposing regulation of hepatobiliary efflux transporters in response to diabetes and pregnancy and points to PPARγ, Nrf2, and FXR as candidate pathways underlying the differential expression of transporters.
Authors: Vincent Zimmer; Roman Müllenbach; Eva Simon; Clemens Bartz; Siegfried Matern; Frank Lammert Journal: Liver Int Date: 2009-09 Impact factor: 5.828
Authors: Johanna Weiss; Alexandra Sauer; Melanie Herzog; Rainer H Böger; Walter E Haefeli; Ralf A Benndorf Journal: Pharmacology Date: 2009-09-24 Impact factor: 2.547
Authors: Lauren M Aleksunes; Scott A Reisman; Ronnie L Yeager; Michael J Goedken; Curtis D Klaassen Journal: J Pharmacol Exp Ther Date: 2010-01-19 Impact factor: 4.030
Authors: Michael T Nowicki; Lauren M Aleksunes; Sharmilee P Sawant; Ankur V Dnyanmote; Harihara M Mehendale; José E Manautou Journal: Drug Metab Lett Date: 2008-01
Authors: Jonathan M Maher; Lauren M Aleksunes; Matthew Z Dieter; Yuji Tanaka; Jeffrey M Peters; Jose E Manautou; Curtis D Klaassen Journal: Toxicol Sci Date: 2008-08-29 Impact factor: 4.849
Authors: Amanda S Bright; Guadalupe Herrera-Garcia; Jamie E Moscovitz; Dahea You; Grace L Guo; Lauren M Aleksunes Journal: Nucl Receptor Res Date: 2016
Authors: Ronald G Udasin; Xia Wen; Kristin M Bircsak; Lauren M Aleksunes; Michael P Shakarjian; Ah-Ng Tony Kong; Diane E Heck; Debra L Laskin; Jeffrey D Laskin Journal: Toxicol Sci Date: 2015-10-09 Impact factor: 4.849
Authors: Ai-Ming Yu; Magnus Ingelman-Sundberg; Nathan J Cherrington; Lauren M Aleksunes; Ulrich M Zanger; Wen Xie; Hyunyoung Jeong; Edward T Morgan; Peter J Turnbaugh; Curtis D Klaassen; Aadra P Bhatt; Matthew R Redinbo; Pengying Hao; David J Waxman; Li Wang; Xiao-Bo Zhong Journal: Acta Pharm Sin B Date: 2017-02-01 Impact factor: 11.413